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Abstract 
A 30-year-old manufacturing process for the biologic product L-asparaginase from the 
plant pathogen Erwinia chrysanthemi was rigorously qualified and validated, with a high 
level of agreement between validation data and the 6-year process database. L- 
asparaginase exists in its native state as a tetrameric protein and is used as a 
chemotherapeutic agent in the treatment regimen for Acute Lymphoblastic Leukaemia 
(ALL). The manufacturing process involves fermentation of the production organism, 
extraction and purification of the L-asparaginase to make drug substance (DS), and finally 
formulation and lyophilisation to generate drug product (DP). The extensive 
manufacturing experience with the product was used to establish ranges for all process 
parameters and product quality attributes. The product and in-process intermediates were 
rigorously characterised, and new assays, such as size-exclusion and reversed-phase 
UPLC, were developed, validated, and used to analyse several pre-validation batches. 
Finally, three prospective process validation batches were manufactured and product 
quality data generated using both the existing and the new analytical methods. These data 
demonstrated the process to be robust, highly reproducible and consistent, and the 
validation was successful, contributing to the granting of an FDA product license in 
November, 2011. 
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1. Introduction 
 
L-asparaginase is routinely used in chemotherapeutic regimens for the treatment of ALL 
[1], to enzymatically convert the amino acid asparagine to aspartic acid. As asparagine is 
essential for growth of leukaemic cells, the L-asparaginase lowers circulating levels of 
asparagine, thereby depriving the cancerous cells of this amino acid [2]. Clinically, L- 
asparaginase preparations from two species are available (Escherichia coli and Erwinia 
chrysanthemi). Although most ALL patients receive the E. coli L-asparaginase, a 
significant proportion of those patients develop a hypersensitivity to it [3, 4]. In these 
cases, treatment with the E. chrysanthemi L-asparaginase may be pursued. 
Erwinase® or Erwinaze® are the proprietary names for L-Asparaginase derived from E. 
chrysanthemi. The E. chrysanthemi L-asparaginase exists as a 140,000 Da tetramer in its 
active form which consists of four identical subunits, and has an isoelectric point of pH 
8.6[5]. The product was first developed in the late 1960s and early 1970s [6,7] and has 
been marketed in many countries around the world. Erwinase® was first approved in the 
UK by the Medicines Control Agency (now the MHRA) in 1986, and is manufactured by 
the Health Protection Agency (formerly Centre for Applied Microbiology & Research) at 
Porton Down, UK. The product is marketed and sold by EUSA Pharma, and until 
recently, was not available commercially in the US; it was only available there under a 
treatment IND. In 2010, a Biologics License Application (BLA) was submitted to the US 
FDA for the product by EUSA Pharma, and in November 2011 the product was approved 
by the US FDA. 
The E. chrysanthemi L-asparaginase manufacturing process (Fig. 1) has not been altered 
significantly since UK licensure in 1986.   The process consists of four main stages: 
fermentation, extraction, purification and formulation. After each of these major process 
stages, intermediates may be held frozen prior to further processing. 
Process validation is a regulatory requisite for registering new biopharmaceutical products 
for human use, to show that manufacturing processes are under control and produce 
materials that are consistent, safe and efficacious. In 1987 and also later in 2011, the US 
FDA published [8, 9] guidance documents that detail the procedures and practices 
necessary to validate biological manufacturing processes. Often, these principles are 
applied to the scale-up of new biopharmaceutical entities with little manufacturing or 
clinical experience. However, process validation may also be applied retrospectively to 
existing processes, developed prior to the issue of these regulatory guidances. In addition 
to the regulatory requirements, process validation may have additional benefits to 
manufacturers of licensed biopharmaceutical products, including greater process 
understanding and, potentially, better process yields. 
Recently, in line with on-going continuous improvement efforts, a programme of process 
validation was undertaken for the production of E. chrysanthemi L-asparaginase. In 
contrast to new biopharmaceutical products, there was an extensive history of 
manufacturing and clinical experience available for this product. This historical database 
was translated into an effective process validation strategy. The validation of the E. 
chrysanthemi L-asparaginase process, described in detail below, confirmed that the 
material produced by this process is consistent and of high product quality. 
  
2. Materials and Methods 
 
2.1 E. chrysanthemi L-asparaginase Manufacturing Process Description 
 
E. chrysanthemi L-asparaginase is manufactured using a four-stage process (fermentation, 
extraction, purification and formulation) as shown in Figure 1. The fermentation stage 
begins with expansion of a vial of E. chrysanthemi from the working cell bank (WCB) to 
produce a working seed inoculum. The inoculum is further expanded in a 50 L 
intermediate fermentation before the production fermentation at 750 L scale. Cells are 
harvested from the production fermentation by continuous flow centrifugation to form a 
cell paste, which is stored frozen. The extraction stage comprises processing of 
approximately three lots of cell paste by cell lysis, an L- asparaginase capture using 
cation-exchange resin and ultrafiltration to yield a crude enzyme preparation. During the 
purification stage (Fig. 2), approximately ten extracts (equivalent to thirty fermentations) 
are pooled and processed through a series of column chromatography and other protein 
purification steps to yield a single batch of purified asparaginase DS. The DS may be 
stored frozen until required for formulation, during which the DS is lyophilised to form the 
final DP presentation. 
 
 
 
2.2 Description of Analytical Methods 
 
Unless otherwise indicated, samples for analysis were derived from the E. chrysanthemi 
L-asparaginase manufacturing process described above. The protein content of these 
samples was determined using a validated method based on the technique of Lowry [10]. 
The asparaginase activity assay is based on the Berthelot reaction and methods described 
in the literature [11,12]. SDS-PAGE analysis was conducted using standard techniques 
with Invitrogen™ (Paisley, UK) Novex™ 4 – 12% Bis-Tris gels, Novex™ MES running 
buffer, reducing agent and LDS sample buffer and Invitrogen™ SimplyBlue™ safestain 
staining reagent. Size-exclusion HPLC assays were performed using a TSK gel 
G3000SWXL column (Tosoh, King of Prussia, PA, USA) and a Waters HPLC 
workstation (Elstree, UK). The reversed-phase HPLC assays were conducted using a 
Waters Acquity™ UPLC 1.7 µm, 300 Å, 2.1 x 100 mm column and a Waters UPLC 
workstation. 
 
 
 
2.3 Process Validation Strategy 
 
The process validation exercise for E. chrysanthemi L-asparaginase required an approach 
different to that applied to new processes.  This was due to the unusual situation of having 
a large body of manufacturing and clinical data extending over many years prior to 
performing this process validation study. The historical manufacturing database utilised 
consisted of eight purification batches (sequentially numbered A-H), corresponding to 
approximately six years of manufacturing experience. As multiple fermentation  cell 
pastes are used to make one L-asparaginase purification batch, this database included 
approximately 300 fermentation batches. These historical data were compiled and 
analysed prior to running three prospective process validation batches. A flow chart 
depicting the process validation strategy is shown in Figure 3. 
During the manufacture of E. chrysanthemi L-asparaginase, there are process parameters 
which are controlled within specified ranges in order to make product that meets pre- 
defined specifications for quality attributes. These process parameters are the ‘inputs’ to 
the process which have acceptable ranges defined in the batch manufacturing instructions 
and in the product licenses and, in the main, cannot be deviated from. Quality attributes 
are the ‘outputs’ of the process and are measurements of the characteristics of the 
intermediates or final product. Examples of process parameters and quality attributes for 
three key L-asparaginase manufacturing steps are shown in Table 1. The historical data 
from the quality attributes for the entire E. chrysanthemi L-asparaginase manufacturing 
process were analysed and ‘windows of operation’ were generated using standard 
statistical methods as described later. 
For the purposes of increased process understanding during the validation exercise, 
additional analytical techniques were developed beyond the historical product quality 
attributes listed in Table 1. The new analytical techniques are listed in Table 2 and were 
designed to provide information on protein aggregation, oxidation, charge variants, 
impurities, and the presence of other excipients and reagents present at various stages 
during manufacture. As there was no existing database for these new analytical 
techniques, setting specifications prior to process validation was not possible. Therefore, 
two purification batches (G and H) were fully analysed using the new techniques. The 
new data were used as guidance for the prospective process validation batches and to help 
set specifications for these methods for future manufacturing campaigns. Example data 
generated using these new methods are shown below in Results. 
Based on the analyses of the historical database, and the application of the new analytical 
techniques, a process validation protocol was written. This protocol established how three 
prospective purification batches (as well as the associated approximately 90 fermentation 
batches and 30 product extraction batches) would be produced, analysed and the expected 
ranges for in-process and DS and DP data. In this paper, only the DS stages of the process 
are discussed. 
3.1 Results 
 
3.2 Understanding the Historical Process 
 
The historical database (consisting of eight purification batches incorporating 
approximately 300 fermentations) was analysed to determine the normal process variance. 
This was performed for the multitude of various product quality measurements which are 
routinely captured during E. chrysanthemi L-asparaginase manufacture. Selected 
examples are presented below to illustrate the approach taken for analysis of the historical 
data. 
Historical data are presented in Figure 4 for two product quality attributes (culture age and 
specific activity) from the fermentation stage of the process. Each point in the graphs 
represents a data point from one fermentation batch. The culture age represents the total 
process time spent in the production fermenter before the fermentation process end points 
(600 nm absorbance plateau and step change in CO2 evolution) are achieved. The culture 
age specification range for this process is 8 – 18 hours, but it is clear from the presentation 
of the historical data that actual operation occurs in a much narrower window. In Figure 
5, historical data are presented for two product quality attributes (total protein and specific 
activity) from the cation-exchange chromatography step. Although in Figure 4B it may 
appear that there is a slight upwards trend in the specific activity over time, this may 
simply be due to slight variations in complex raw materials such as yeast extract, and in 
subsequent batches (data not shown) this trend did not continue. 
The data in these Figures show the normal variation in these attributes over the course of 
manufacture of the historical batches and illustrate the batch-to-batch reproducibility of 
the Erwinia L-asparaginase production process. The mean and standard deviation (SD) of 
the data were calculated for each of these quality attributes.  The mean, mean ± two SD 
and mean ± three SD are plotted along with the data points. For these data, the mean ± 
three SD values are taken to be the normal ‘operating window’ for each parameter, since 
the data in most cases are well described by a normal distribution around the mean. For 
example, the 98.3% of the data in Figure 4A are within ± two SD and 99% are within ± 
three SD. 
 
 
 
3.3 Process Validation 
 
Once the historical ‘operating windows’ were established for the various process 
parameters and quality attributes, process validation batches were conducted. Three 
prospective process validation batches were conducted at the purification stage. However, 
approximately thirty fermentation batches are required to make one lot of drug substance, 
so in order to make these three process validation batches in the purification and drug 
product stages of the process, ninety fermentation batches had to be made. Due to the 
large number of batches, process parameters and quality attributes studied during 
validation, only a small subset of the data are provided here. 
The fermentation stage of the process showed a high degree of consistency during the 
process validation batches with the data in reasonable agreement (Figure 6) with the 
historical operating windows. The specific activity data at fermentation harvest (Figure 
6B), tare observed to largely comply with the historical operating windows.  Interestingly, 
a step change was observed during process validation in the culture age (or process time) 
of the fermentation step (Figure 6A). Although the culture ages for all fermentation 
batches shown in the figure were within the specification limits of 8 – 18 hours, the step 
change resulted in process performance outside the narrow historical operating windows. 
These step changes were also observed in the culture age data for the inoculum fermenter 
(data not shown) and were shown due to introduction of a new batch of yeast extract at the 
time. This raw material is common to both inoculum and production culture steps. Some 
variability in fermentation processes due to raw materials is to be expected, and has been 
specifically discussed for fermentation of Erwinia using complex media, where small 
changes in media components may have a dramatic effect on enzyme production and 
growth [13]. The slight change in culture age had no impact on the product quality at DS 
(data not shown). As the step change in the data could be easily explained, it was not 
considered to negatively influence the process validation exercise. 
Similarly, for the purification stage of the process, the prospective validation data showed 
good agreement with the historical operating windows and demonstrated a high degree of 
reproducibility and consistency. Two example data sets are presented here (Figure 7) for 
total protein and specific activity throughout the purification process. In all cases apart 
from the cation-exchange II step, the data agree with the historical operating windows as 
shown in the figure. The process intermediate after the cation-exchange II step had a 
slightly higher specific activity when compared to the data in the historical database. As 
specific activity is a measure of product purity, one batch being slightly more pure than 
expected at this intermediate stage should not be taken as a major process issue and was 
ascribed to normal process or assay variation. The final drug substance for this batch met 
all quality attributes and specifications (data not shown). 
The process validation data generated using the new analytical techniques also showed a 
high degree of batch-to-batch consistency and reproducibility. Many analytical techniques 
were developed to fully characterise the product, and a selection of data are presented 
here. The HPLC-based techniques (Table 3) were used to look at product purity, 
oxidation and aggregation states. SDS-PAGE was also used to show product purity, and 
selected data are shown in Figure 8.   Other analytical techniques were used, such as 
peptide mapping, host-cell protein content, residual DNA content, bioburden content, 
endotoxin content and isoelectric charge variant content (data not shown). Taken together 
as a whole, these data confirm that the Erwinia L-asparaginase manufacturing process is 
consistent and reproducible and results in a product with consistent quality and purity. 
4. Conclusions
Using the process validation strategies detailed in this paper, the manufacturing process 
for Erwinia L-asparaginase was successfully validated. The historical database was 
consulted and for each process parameter or quality attribute, operating windows were 
defined, each consisting of the mean value ± three SD around the mean. New analytical 
techniques were employed to fully characterise the quality of the product and applied to a 
subset of historical batches. Three prospective process validation batches were then 
conducted and characterised using both routine and new analytical methods. The results 
from all these measurements were compared against the historical operating windows (for 
routine measurements) or for new measurements, the existing historical data. All 
analytical measurements performed on the process validation campaign  samples 
confirmed the robustness and reproducibility of the Erwinia L-asparaginase manufacturing 
process. Furthermore, the product quality of both the process intermediates and the final 
drug substance was shown to be reproducible and consistent. In some cases, studying 
process performance using historical operating windows can lead to process 
understanding, such as step changes in performance when new raw materials are 
introduced. 
The results of the process validation of Erwinia L-asparaginase demonstrate that 
combining historical data mining with rigorous application of new analytical techniques, 
older biologic processes can be successfully characterised and validated to comply with 
modern regulations. The framework described in this paper could easily be applied to 
other legacy biopharmaceutical products. As a result of the successful completion of the 
validation programme described above the Erwinia L-asparaginase manufacturing process 
was considered validated, and an US FDA product license was granted for Erwinaze® in 
November, 2011. 
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Figure 1.  E. chrysanthemi L-Asparaginase Manufacturing Process Overview. 
Figure 2.  Overview of Purification Process for E. chrysanthemi L-asparaginase. 
Figure 3.  Overview of Process Validation Strategy for E. chrysanthemi L-asparaginase. 
(A) 
(B) 
Figure 4. Historical Data for the Production Fermentation Stage of Erwinia L- 
asparaginase. Each data point represents one fermentation batch out of approximately 300 
batches. The mean, mean ± 2 standard deviations (SD) and mean ± 3 SD are also plotted 
with the data points. (A) Culture Age of Production Fermenter and (B) Specific L- 
asparaginase activity at harvest. 
(A) 
(B) 
Figure 5. Historical Data for the Cation-Exchange Chromatography of Erwinia L- 
asparaginase. Each data point represents one purification batch out of eight total batches. 
The mean, mean ± 2 standard deviations (SD) and mean ± 3 SD are also plotted with the 
data points. (A) Total Protein Content of Cation-Exchange Product and (B) Specific L- 
asparaginase activity of Cation-Exchange Product. 
(A) 
(B) 
Figure 6. Selected Fermentation Process Validation Data. The data presented are from 
the 90 fermentation batches executed in order to make the 3 process validation purification 
batches. Data in the figures are compared to the statistical operating windows (depicted 
by horizontal lines) established for the historical database. Data are presented for (A) 
production fermentation culture age and (B) specific activity at fermentation harvest. 
(A) 
  (B) 
Figure 7. Example Purification Process Validation Data. Data are shown for each of the 
process validation purification batches, at each intermediate stage of the process. Data in 
the figures are compared to the ± 3 standard deviation operating windows (depicted by 
horizontal lines) established for the historical database. Data are presented for (A) total 
protein and (B) specific activity. 
Figure 8. Coomassie-stained SDS-PAGE images from the Erwinia L-asparaginase 
Purification Process Validation campaign.  The product is shown after the cation-exchange 
I step and at final drug substance. In all gel images, lanes 1 and 8 (reading from left to 
right) are the molecular weight markers, lanes 2 and 7 are the reference standard (ERS), 
lane 3 is the intensity standard (representing a 2% or 20 ng load) and lanes 4 – 6 (marked 
with ‘test’) are the sample run in triplicate.  The loading of each standard and test well is 1 
µg.  The data show the reproducibility and robustness of the purification. 
Table 1. Historical Process Parameters and Quality Attributes for the Fermentation, 
Cation Exchange I Chromatography, and Ammonium Sulphate Precipitation steps in the 
manufacture of E. chrysanthemi L-asparaginase. 
Process Step Process Parameters Quality Attributes 
Production 
Fermentation 
 Media Composition
 Fermentation pH
 Dissolved Oxygen
Content
 Temperature
 Agitation Rate
 Airflow
 Antifoam Feed Rate
 Evolved CO2 
Profile
 600 nm Absorbance at
Start
 600 nm Absorbance at
Harvest
 Fermentation Duration
 Growth rate
 Doubling time
 Asparaginase Activity at
Harvest
 Asparaginase Specific
Activity
 Cell dry weight at
Harvest
 Viable Cell Count
Cation 
Exchange 
Chromatography 
 Flow Rate
 Bed Height
 Column Load (g
protein/L resin)
 Buffer pH
 Temperature
For Column Eluate: 
 Asparaginase Activity
 Protein concentration
 Specific activity
 Total activity
 Endotoxin
 Bioburden
Ammonium 
Sulphate 
Precipitation 
 Amount of
(NH4)2SO4 added
 Precipitation Time
 Centrifuge Speed
 Redissolution
Volume
 pH
 Asparaginase Activity
 Protein concentration
 Specific activity
 Total activity
 Endotoxin
 Bioburden
Table 2. New Analytical Techniques Developed for Product Quality Assessment During 
Process Validation. The same assays were applied to purified Drug Substance as well as 
other product intermediate stages. 
Process Step Technique Purpose 
Cation 
Exchange 
Chromatography 
Reversed-Phase UPLC Product Oxidation, Impurities 
Weak Cation-Exchange 
HPLC 
Product Charge Variants 
Size-Exclusion HPLC Product Aggregation 
SDS-PAGE Impurities 
DNA Content by Pico- 
GreenTM 
Host Cell DNA 
Contamination 
Host-Cell Protein ELISA Non -L-asparaginase Erwinia 
protein detection 
Table 3. Selected Profiling Batch Historical and Process Validation Data using New 
Analytical Methods. The data show the area percent of the main L-asparaginase peak. 
The Reversed-Phase method characterises the product with respect to oxidised species and 
impurities. The Size-Exclusion method characterises the product with respect to 
aggregates. The tetrameric form of the L-asparaginase is the active  species.  N/m 
indicates that the method is not suitable for product at this stage of processing. 
Process 
Intermediate 
Batch Series L-asparaginase 
Purity by 
Reversed-Phase 
HPLC 
Percent 
Tetrameric L- 
asparaginase by 
Size Exclusion 
Extract Historical  Profiling  (G 
– H) 
36 – 40% N/m 
Process Validation (I – 
K) 
38 – 47% N/m 
Cation-Exchange 
I Product 
Historical  Profiling  (G 
– H) 
87 – 91% N/m 
Process Validation (I – 
K) 
89 – 93% N/m 
Cation-Exchange 
II Product 
Historical  Profiling  (G 
– H) 
92 – 95% 98 – 99% 
Process Validation (I – 
K) 
94 – 96% 100% (n=3) 
Anion-Exchange 
Product 
Historical  Profiling  (G 
– H) 
93 – 94% 99% (n=2) 
Process Validation (I – 
K) 
94 – 95% 100% (n=3) 
Drug Substance Historical  Profiling  (G 
– H) 
94 – 95% 100% (n=2) 
Process Validation (I – 
K) 
94 – 95% 100% (n=3) 
